TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04194723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antireflux Mucosectomy
Description: ARMS aimed at resection of mucosa at gastric cardia to induce fibrosis and tighten the gastroesophageal junction and reduce acid reflux
Study: NCT02953665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg
Study: NCT04366557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy, exercises and education program
Description: a six week body posture therapy consisted of manual therapy (once per week) and home exercises; education about pelvic floor

Intervention type: OTHER
Group type: OTHER
Intervention: Education program
Description: education about pelvic floor
Study: NCT03033953

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Native whey

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strength training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Study: NCT02725242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide (400μg/d)
Description: After the patients who have all criteria, they will be randomization to take Budesonide (200 ug) twice daily
Study: NCT02071888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Glutaminase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Glutaminase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Glutaminase inhibitor
Study: NCT01878786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF/MPA)
Description: Control Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF/MPA)
Description: Control Drug
Study: NCT02071888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839 and low dose dexamethasone
Description: CB-839 and low dose dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839 and low dose dexamethasone
Description: CB-839 and low dose dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839, pomalidomide, and low dose dexamethasone
Description: CB-839, pomalidomide, and low dose dexamethasone
Study: NCT00907985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo will be provided.
Study: NCT02773511

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical treatment
Description: Closed reduction and Kirschner wire fixation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical treatment
Description: Closed reduction and Kirschner wire fixation
Study: NCT04511793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Synchromed II pump
Description: The pump will be placed during surgery and the pump will be filled with a combination of floxuridine (FUDR), dexamethasone, heparin, and saline.
Study: NCT03159481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care + Health Promotion Intervention
Description: Telephone sessions for approximately 5-6 weeks to enhance empowerment and skills for managing medication adherence.
Study: NCT00888095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation
Description: electrode implantation in either STN or cZI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation
Description: electrode implantation in either STN or cZI
Study: NCT02742987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 90 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 150 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medical therapy
Description: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medical therapy
Description: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
Study: NCT00847457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercises completed three to four times per week for 20 to 30 minutes per session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Easy to moderate stretching routines completed three times per week, with a new set of routines given each week
Study: NCT02221375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHT low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHT medium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHT high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903 XX low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903 XX medium 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903 XX medium 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903 XX medium 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903 XX high

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Study: NCT03839212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOLA Component 1
Description: At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOLA Component 2
Description: A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOLA Component 3
Description: A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOLA Component 4
Description: One booster walking session twice a month for three months post intervention for reinforcement.
Study: NCT00452829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid and inositol
Description: Folic Acid and inositol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid and placebo
Description: Folic acid and placebo
Study: NCT03384979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopamidol
Description: Contrast agent will be adrministered intravenously using total body weight or lean body weight, calculated with bioelectrical impedance analysis balance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iopamidol
Description: Contrast agent will be adrministered intravenously using total body weight or lean body weight, calculated with bioelectrical impedance analysis balance.
Study: NCT01607996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: Epidural will be performed using carbostesin (0.1%), fentanyl (2 microg/ml) administered continuously at a rate of 6 to 15 ml/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled intravenous analgesia
Description: Fentanyl 10 microg/ml at continuous flow of 10 to 20 microg/hour
Study: NCT02768636

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: Omega-3 or Fish oil (1000 mg.) is taken for one capsule a day in 30 days duration. Heart rate variability is tested before at starting day and later follow up it again in the next 30 days appointment.
Study: NCT00875966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer
Description: Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
Study: NCT02677506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supraclavicular
Description: Brachial plexus block with supraclavicular approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular
Description: Brachial plexus block with infraclavicular approach
Study: NCT01327924

Intervention type: DRUG
Intervention: Norditropin NordiFlex®
Description: Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
Study: NCT03000413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Active treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study: NCT03703661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle-Aspirated Negative Pressure Dressing
Description: dressing consisting of Needle-Aspirated Negative Pressure dressing with gauze and adhesive/occlusive dressing, placed over wound after primary closure

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: dressing consisting of gauze and adhesive/occlusive dressing, placed over wound after primary closure
Study: NCT00601510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study: NCT02557633

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass MATA MPL 10200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass MATA MPL 18200

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03089489

Intervention type: DIAGNOSTIC_TEST
Intervention: lung biomarkers in organ donor for PGD in lung recipient
Description: Lung biopsies in organ donor before and after cold ischemia

Intervention type: DIAGNOSTIC_TEST
Intervention: lung biomarkers in organ donor for PGD in lung recipient
Description: Lung biopsies in organ donor before and after cold ischemia
Study: NCT03459794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: 150 mcg/kg ivermectin, by mouth.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral placebo will be administered, once
Study: NCT02364999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-Pfizer
Description: Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab-EU
Description: bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.
Study: NCT00606931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereo Navigator Accessory to PEM Flex PET Scanner
Description: For patients with suspicious breast abnormalities seen on high resolution PET image, the patients will be biopsied using commercial vacuum biopsy devices (pre-validated to work with Stereo Navigator) using Naviscan's Stereo Navigator (interventional device) for PET image guidance.
Study: NCT03729128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan and memantine (DM+MM)
Description: Patients of Amphetamine-type stimulants use disorder (ATSUD) will take dextromethorphan 30 mg/day and memantine 5 mg/day combination (DM+MM) daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients of Amphetamine-type stimulants use disorder (ATSUD) will take placebos daily for 12 weeks.
Study: NCT01935622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 1 tablet every 12 hours for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 1 tablet every 12 hours for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 1 tablet every 12 hours for 14 days
Study: NCT01676428

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The investigational treatment will be prescribed as a 2-tiered dose scheduled dependant on target size.~For lesions \<5cm, a single fraction of 26Gy will be prescribed. For lesions ≥5cm a fractionated course of 14Gy by 3 fractions will be prescribed, delivered at least 48 hours apart.
Study: NCT03436095

Intervention type: OTHER
Intervention: bundle measures
Description: Implementation of bundle measures to improve the successful rate of weaning ventilator

Intervention type: OTHER
Intervention: bundle measures
Description: Implementation of bundle measures to improve the successful rate of weaning ventilator

Intervention type: OTHER
Intervention: bundle measures
Description: Implementation of bundle measures to improve the successful rate of weaning ventilator
Study: NCT00793715

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompressive laparotomy with temporary abdominal closure
Description: Surgical intervention including midline incision with temporary abdominal closure and several planed staged relaparotomies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous puncture with placement of abdominal catheter
Description: Installation of abdominal catheter percutaneously via abdominal centesis 2cm bellow the umbilicus
Study: NCT03735004

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial electrostimulation (TES)
Description: Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC) current, or TES with DC only will be administered through the skin electrodes positioned on the patient's head
Study: NCT05066802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant modified FOLFIRINOX
Description: oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42\~46h continuous infusion, every other week for 6 cycles (12 weeks) before surgery.
Study: NCT03112642

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic block [0.35% marcaine]
Description: In the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block \[0.35% marcaine\] will be administered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthetic block [0.35% marcaine]
Description: In the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block \[0.35% marcaine\] will be administered.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Braun DIG-R-C Stimuplex Blockade Monitor System
Description: The blockade system will be initially set at 1 milliamp. As the proximity of the tip of the needle to the components of the brachial plexus becomes evident by ultrasound approximation and the stimulation pattern of the hand and wrist, the output of the system will be reduced to .3-.5 milliamps. With use of the Braun DIG-R-C Stimuplex Blockade Monitor System.
Study: NCT00073697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Participants will receive escitalopram for a minimum of 32 weeks or approximately 8 months. Participants whose symptoms become stabilized will continue the initial treatment for another 6 months.
Study: NCT03514784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BB-12 with LGG (Higher Dose)
Description: BB-12 with LGG - Higher Dose (10 billion CFUs)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BB-12 with LGG (Lower Dose)
Description: BB-12 with LGG - Lower Dose (1 billion CFUs)
Study: NCT01975909

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: 0.2 Hz (5 pulses every six seconds in a counter-clockwise current, followed by the same five pulses in a clockwise current); 10 pulses per region, 30 pulses per session; 5 days a week for 4 weeks.
Study: NCT00073697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: Participants will receive interpersonal psychotherapy (IPT) for 8 months and possibly an additional 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Escitalopram plus IPT
Description: Participants whose symptoms become stabilized will continue the initial treatment for another 6 months. Those who do not will have the second treatment added to their regimen until remission occurs.
Study: NCT01975909

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: 0.2 Hz (5 pulses every six seconds in a counter-clockwise current, followed by the same five pulses in a clockwise current); 10 pulses per region, 30 pulses per session; 5 days a week for 4 weeks.
Study: NCT00567892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)
Study: NCT02265926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N95 mask
Description: N95 mask material used to cover aperture of Hans Rudolph mask
Study: NCT03537131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 MG Oral Tablet
Description: taken once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 MG Oral Tablet
Description: taken once a day
Study: NCT03252561

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Transversus Abdominis Plane (TAP) bock
Description: Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anaesthetic infiltration of laparoscopic port sites
Description: Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
Study: NCT02256436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinflunine
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: IV infusion
Study: NCT01831102

Intervention type: OTHER
Intervention: none- observational study

Intervention type: OTHER
Intervention: none- observational study
Study: NCT01517958

Intervention type: OTHER
Intervention: Respiratory Distress Group
Description: Diagnostic lung ultrasound.

Intervention type: OTHER
Intervention: Control Group
Description: Lung ultrasound
Study: NCT01704274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Dose GTN 0.0285 mg/hr
Description: Low Dose GTN
Study: NCT00862329

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein-enriched diet
Description: Subjects consume for 9 days a supplement of 30g/d of casein
Study: NCT01704274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Dose GTN 0.057 mg/hr
Description: High Dose GTN

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00100308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractioned heparin
Description: Low-dose continuous-infusion, 500 units/hour per seven days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline placebo
Study: NCT00633347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antagonist GnRH Cetrotide
Description: Cetrotide 0.25 mg. daily/ 7 days